EBV-specific T cells (EBV-CTLs)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EBV-induced Lymphomas
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Trial Timeline
Dec 1, 2011 → Jul 1, 2019
NCT ID
NCT01498484About EBV-specific T cells (EBV-CTLs)
EBV-specific T cells (EBV-CTLs) is a phase 2 stage product being developed by Atara Biotherapeutics for EBV-induced Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01498484. Target conditions include EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma.
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01498484 | Phase 2 | Completed |
Competing Products
1 competing product in EBV-induced Lymphomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Atara Biotherapeutics | Phase 1/2 | 22 |